Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $18 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $2 | $1 | $0 |
| Enterprise Value | $0 | $2 | $20 | $1 |
| Revenue | $3 | $2 | $3 | – |
| % Growth | 32.2% | -26.6% | – | – |
| Gross Profit | $1 | $1 | $1 | – |
| % Margin | 38.5% | 39% | 40.9% | – |
| EBITDA | -$1 | -$2 | -$0 | – |
| % Margin | -20.7% | -113.5% | -5.5% | – |
| Net Income | -$4 | $1 | -$0 | – |
| % Margin | -139.3% | 34.8% | -7.4% | – |
| EPS Diluted | -0.019 | 0.009 | -0.009 | – |
| % Growth | -308.8% | 196.8% | – | – |
| Operating Cash Flow | – | -$0 | $0 | – |
| Capital Expenditures | – | -$1 | -$0 | – |
| Free Cash Flow | – | -$1 | -$0 | – |